Sustanon 250 (testosterone blend) — Dosing, Cycles, Half-Life & Side Effects

Quick Facts

Typical Dosing Ranges

Common dose range: 250-500mg per week (every 5-7 days)

Cycle length: 10-16 weeks

Time to steady state: ~70 days

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

• No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.

PCT Requirements

• This compound causes clinically meaningful HPTA suppression. Post-cycle therapy is recommended.
• Depot clearance estimate: ~70 days post-last-dose before SERM start (5 × apparent depot half-life of 336h).
• Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
• Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

• Complex PK makes dose adjustment imprecise
• Contains multiple esters each with different half-lives

Known Interactions

• Testosterone Cypionate + Letrozole

  minor — pharmacokinetic

  Letrozole is potent AI. Over-suppression of estrogen is possible.

  Recommendation: Start with very low doses. Monitor E2 closely to avoid crash.

  Monitor: Estradiol, Joint pain, Mood

• Testosterone Cypionate + Primobolan (Methenolone Enanthate)

  minor — synergistic

  Good synergy with low sides. Common stack.

  Recommendation: Generally well-tolerated combination.

  Monitor: Standard bloodwork

Related compounds

• Testosterone Cypionate

  Esters · t½ 7-8 days (apparent depot half-life; elimination half-life ~4 days for de-esterified testosterone)

• Testosterone Enanthate

  Esters · t½ 4-5 days (elimination half-life; apparent half-life 7-10 days due to slow release from depot)

• Testosterone Propionate

  Esters · t½ 0.8 days

• Testosterone Phenylpropionate

  Esters · t½ 4-5 days (phenylpropionate ester; ester-chain extrapolation from Minto 1997 nandrolone PK data)

Monitoring (Bloodwork & Vitals)

• Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
• Lipid panel (total cholesterol, HDL, LDL, triglycerides)
• CBC (hemoglobin, hematocrit — watch for erythrocytosis)
• Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
• Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

Citations

1. Minto CF et al.. 1997. J Pharmacol Exp Ther — Ester-chain PK extrapolation - Sustanon 250 composite (propionate/phenylpropionate/isocaproate/decanoate) produces continuous release with effective half-life ~14 days
2. Behre HM et al.. 2004. Testosterone: Action, Deficiency, Substitution — Sustanon 250mg every 2-3 weeks provides physiologic testosterone replacement; supraphysiologic cycles 250-1000mg/week
3. de Oliveira Vilar Neto JF et al.. 2021. Andrologia — AAS-induced hypogonadism from testosterone blend therapy - supports suppressionScore 10/10
4. Bhasin S et al.. 2001. Am J Physiol Endocrinol Metab — Estradiol dose-dependent rise with supraphysiologic testosterone blend; supports aromatizationRate 6/10
5. Hartgens F, Kuipers H. 2004. Sports Medicine — Sustanon injectable testosterone blend - minimal hepatic impact; supports hepatotoxicity 0/10
6. Liu E et al.. 2025. Subst Use Misuse — AAS CV risk meta-analysis - blend testosterone has comparable CV profile to single-ester formulations
7. Sustanon 250 package insert (FDA/EMA) - composite ester PK